share_log

Wells Fargo Maintains Overweight on NovoCure, Lowers Price Target to $42

Moomoo 24/7 ·  Apr 3 12:43

Wells Fargo analyst Larry Biegelsen maintains NovoCure (NASDAQ:NVCR) with a Overweight and lowers the price target from $49 to $42.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment